Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment

Inclusion Criteria: * Hepatically impaired groups: * Agree to doctor approved birth control methods from Day 1 until 3 months following the final dose of study drug. * Have mild hepatic impairment (Child-Pugh Clinical Assessment Score Grade A, score 5 6) or moderate hepatic impairment (Child-Pugh Clinical Assessment Score Grade B, score 7-9) or severe hepatic impairment (Child-Pugh Clinical Assessment Score Grade C, score 10-15); * Control group * Agree to doctor approved birth control methods from Day 1 until 3 months following the final dose of study drug. * Healthy as determined by medical history, physical exam, vital signs, ECGs, and clinical laboratory tests. Exclusion Criteria: * Hepatically impaired groups: * Have used any drugs known to significantly affect hepatic metabolism within 28 days, or is unable or unwilling to forgo the use of such products throughout the study; * Have any acute or unstable condition or disease, other than impaired hepatic function, as determined by medical history, physical exam, ECG and clinical laboratory tests; * Known ongoing alcohol and/or drug abuse within 1 month * Any evidence of progressive worsening liver function disease as indicated by laboratory values; * Have had an acute flare of hepatitis A or B within 6 months; * Have acute, fulminant alcoholic hepatitis, determined either clinically or by histology; * Have a history of hepatoma or metastatic disease of the liver; * Control group: * Have used any drugs known to significantly affect hepatic metabolism within 28 days, or is unable or unwilling to forgo the use of such products throughout the study; * Have a history or presence of clinically cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, psychiatric, pulmonary, or renal disease or any other condition.